IDDI at Eyecelerator AAO 2022
October 1, 2022 — October 3, 2022
Linda Danielson, Chief Operating Officer of IDDI is representing IDDI at this year’s Eyecelerator @ AAO 2022 in Chicago, USA from 1 – 3 October!
Schedule a meeting with IDDI’s Chief Operations Officer Linda Danielson to connect and discuss how we can leverage your upcoming ophthalmology drug or device development!
IDDI has long-standing experience in OPHTHALMOLOGY with 145+ trials since inception – IDDI supported Macugen® approval.
- Our valuable therapeutic insight in ophthalmology, paired with data quality expertise, will make a critical difference to the outcome of your clinical trials.
- Our scientific background, experienced teams and in-house therapeutic expertise will provide you with effective study design, start-up and management.
- IDDI’s broad range of expertise is reflected in its expert publications in various medical and statistical journals and through its presence at major meetings and congresses (list provided on request).
- IDDI’s in-depth experience had been gained from involvement in over 1200+ clinical trials across a wide range of therapeutic areas – handling drug, diagnostic and medical device issues, as well as assisting clients in obtaining 21 FDA/EMA approvals.
About the event:
Eyecelerator, a partnership between the American Academy of Ophthalmology and ASCRS, advances innovation in eye care by connecting mission-driven entrepreneurs, investors, physicians, and global strategic executives through next-generation business conferences.
View the full proramm of Eyecelerator @ AAO 2022 here.